4th Annual Gene Therapy Analytical Development Europe

Memo

Uniting leading CMC, Regulatory, QC, Analytical and Process Development experts, the 4th Annual Gene Analytical Development Europe Summit is the industry's definitive and only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development. Hear from the likes of AstraZeneca, MHRA, Gyroscope, REGENXBIO, Biogen, Spark Therapeutics, and more across three days and two tracks of in-depth case studies, interactive panel discussions, dedicated Q and A time, and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. Don't miss the opportunity to network with 80+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle. URLs:Tickets: https://go.evvnt.com/1485210-2?pid=5569Brochure: https://go.evvnt.com/1485210-3?pid=5569 Date and Time: On Tue, May 2, 2023 ( 9:00 AM) - Thu, May 4, 2023 ( 4:00 PM) Venue details: The Tower Hotel, St Katharine's Way, London, England, E1W 1LD, United Kingdom Prices:2 Day Conference + Pre Conference Workshop Day - Standard Pricing: GBP 4397.00,2 Day Conference Only - Standard Pricing: GBP 3099.00,2 Day Conference + Workshop Day - Drug Developer Pricing: GBP 3697.00,2 Day Conference Only - Drug Developer Pricing: GBP 2599.00 Speakers: Alicja Fiedorowicz, Consultant, Independant, Cullen Mason, Senior Scientist, Biogen, Cynthia Brysch, Senior Director - Quality, Sarepta Therapeutics, Damon Barbacci, Analytical Development Lead, Spark Therapeutics, David Dobnik, Senior Associate - Research and Researcher, National Institute of Biology, Dwayne Neal, Senior Director - Analytical Sciences, AVROBIO, Eric Yearley, Associate Director, Bridge Bioscience Corp, Franz Schnetzinger, Vice President - Quality Control Analytical Development, Gyroscope, Janet Glassford, Expert Quality Assessor, Medicines and Healthcare Products Regulatory Agency (MHRA), Jeroen van der Velden, Team Lead Assay Development, Amarna Therapeutics, Jinpu Yang, Senior Manager - Analytical Development, Vertex Pharmaceuticals, Juan Sanchez, Nieto Senior Scientist, Orchard Therapeutics, Kam Tse, Director, PTC Therapeutics, Kun Lu, Sr. Staff Scientist, Regeneron Pharmaceuticals Inc, Marco Thomann, Principal Scientist, Roche Diagnostics GmbH, Pedro Cruz, Chief Technical Officer, IBET - Instituto de Biologia Experimental e Tecnologica, Ping Carlson, Director - Bioassays, Passage Bio, Polona Kogovsek, Researcher, National Institute of Biology, Ryan Smith, British Pharmacopoeia Specialist, Medicines and Healthcare Products Regulatory Agency (MHRA), Sara Potter, Associate Director, Ultragenyx Pharmaceutical Inc, Shana Boyer, Critical Reagent Lead, Spark Therapeutics, Shuai Li, Scientist, Regeneron Pharmaceuticals Inc, Simon Briggs, Head of Gene Therapy Technical Product Development, Biogen Idec, Susumu Uchiyama, Professor, Osaka University, Therese Solstad, Senior Scientific Advisor, Norwegian Medicines Agency, Tomasz Witkos, Associate Director, AstraZeneca, Win Den Cheung, Director Analytical Development, REGENXBIO